Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: Where do we stand?

被引：30

作者：

Agarwal, Vijay ^{[1
,2
,3
]}

Lind, Michael J. ^{[1
,2
,3
]}

Cawkwell, Lynn ^{[1
,2
]}

机构：

[1] Univ Hull, Canc Biol Prote Grp, Postgrad Med Inst, Kingston Upon Hull HU6 7RX, N Humberside, England

[2] Hull York Med Sch, Kingston Upon Hull, N Humberside, England

[3] Hull & E Yorkshire NHS Trust, Queens Ctr Oncol & Haematol, Kingston Upon Hull, N Humberside, England

来源：

CANCER TREATMENT REVIEWS | 2011年 / 37卷 / 07期

关键词：

Epidermal growth factor receptor; Mesothelioma; Predictive biomarkers; Targeted therapy; Tyrosine kinase inhibitors; CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; RANDOMIZED PHASE-II; PREVIOUSLY TREATED PATIENTS; CETUXIMAB PLUS IRINOTECAN; KIRSTEN-RAS MUTATIONS; P53 SUPPRESSOR GENE; COLORECTAL-CANCER; K-RAS; CYCLOOXYGENASE-2; EXPRESSION;

D O I：

10.1016/j.ctrv.2010.11.004

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The median survival for patients with malignant pleural mesothelioma remains extremely poor and there is a need for the development of more effective treatment modalities. The epidermal growth factor receptor is frequently over-expressed in malignant pleural mesothelioma samples and therefore may be a potential therapeutic target. Targeted EGFR therapy has been successful in non-small cell lung cancer using small molecule tyrosine kinase inhibitors and in colorectal cancer using monoclonal anti-EGFR antibodies. However, phase II clinical trials based on EGFR tyrosine kinase inhibitor therapy have so far not shown promise in mesothelioma. This review includes a background to targeted EGFR treatment strategies, explores putative therapy resistance mechanisms, including the role of predictive biomarkers, and describes the current status of targeted EGFR therapeutic strategies for mesothelioma patients. (C) 2010 Elsevier Ltd. All rights reserved.

引用

页码：533 / 542

页数：10

共 116 条

[1]

Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth [J].

Altomare, DA ;

You, HH ;

Xiao, GH ;

Ramos-Nino, ME ;

Skele, KL ;

De Rienzo, A ;

Jhanwar, SC ;

Mossman, BT ;

Kane, AB ;

Testa, JR .

ONCOGENE, 2005, 24 (40) :6080-6089

[2]

Amir M, 2005, PHARMAZIE, V60, P563

[3]

Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].

Andreyev, HJN ;

Norman, AR ;

Cunningham, D ;

Oates, J ;

Dix, BR ;

Iacopetta, BJ ;

Young, J ;

Walsh, T ;

Ward, R ;

Hawkins, N ;

Beranek, M ;

Jandik, P ;

Benamouzig, R ;

Jullian, E ;

Laurent-Puig, P ;

Olschwang, S ;

Muller, O ;

Hoffmann, I ;

Rabes, HM ;

Zietz, C ;

Troungos, C ;

Valavanis, C ;

Yuen, ST ;

Ho, JWC ;

Croke, CT ;

O'Donoghue, DP ;

Giaretti, W ;

Rapallo, A ;

Russo, A ;

Bazan, V ;

Tanaka, M ;

Omura, K ;

Azuma, T ;

Ohkusa, T ;

Fujimori, T ;

Ono, Y ;

Pauly, M ;

Faber, C ;

Glaesener, R ;

de Goeij, AFPM ;

Arends, JW ;

Andersen, SN ;

Lövig, T ;

Breivik, J ;

Gaudernack, G ;

Clausen, OPF ;

De Angelis, P ;

Meling, GI ;

Rognum, TO ;

Smith, R .

BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696

[4]

Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma [J].

Baldi, A ;

Santini, D ;

Vasaturo, F ;

Santini, M ;

Vicidomini, G ;

Di Marino, MP ;

Esposito, V ;

Groeger, AM ;

Liuzzi, G ;

Vincenzi, B ;

Tonini, G ;

Piccoli, M ;

Baldi, F ;

Scarpa, S .

THORAX, 2004, 59 (05) :428-433

[5]

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer [J].

Bardelli, Alberto ;

Siena, Salvatore .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1254-1261

[6]

Epidermal growth factor receptor signaling [J].

Bogdan, S ;

Klämbt, C .

CURRENT BIOLOGY, 2001, 11 (08) :R292-R295

[7]

Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non-small-cell lung cancer [J].

Butts, Charles A. ;

Bodkin, David ;

Middleman, Edward L. ;

Englund, Craig W. ;

Ellison, David ;

Alam, Yasmin ;

Kreisman, Harvey ;

Graze, Peter ;

Maher, James ;

Ross, Helen J. ;

Ellis, Peter M. ;

McNulty, William ;

Kaplan, Edward ;

Pautret, Virginie ;

Weber, Martin R. ;

Shepherd, Frances A. .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (36) :5777-5784

[8]

The pathogenesis of mesothelioma [J].

Carbone, M ;

Kratzke, RA ;

Testa, JR .

SEMINARS IN ONCOLOGY, 2002, 29 (01) :2-17

[9]

CARPENTER G, 1975, J BIOL CHEM, V250, P4297

[10]

Reclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention [J].

Catalano, A ;

Graciotti, L ;

Rinaldi, L ;

Raffaelli, G ;

Rodilosso, S ;

Betta, P ;

Gianni, W ;

Amoroso, S ;

Procopio, A .

INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (03) :322-328

← 1 2 3 4 5 6 7 8 9 10 →